NSE · PPLPHARMA
Piramal Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,125 Cr with net profit ₹113 Cr — a 10.09% net margin, versus -3.59% the period before.
Shareholding
As of 2026-06-30
- Promoter34.8%
- Public38.11%
- FII12.52%
- DII14.57%
4,61,096 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.75× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #18 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,42,173 Cr | 35 | 5.29 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,10,414 Cr | 22.61 | 4.07 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,09,004 Cr | 30.46 | 3.17 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,04,356 Cr | 95.42 | 19.69 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,542 Cr | 25.27 | 2.52 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,345 Cr | 29.59 | 2.5 | 11.07% | 9.73% |
| Lupin Limited | ₹94,430 Cr | 15.85 | 4.21 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,171 Cr | 43.2 | 5.65 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹67,322 Cr | 21.57 | 6.4 | 28.08% | 10.22% |
| Biocon Ltd. | ₹62,922 Cr | 86.18 | 1.83 | 1.14% | 2.89% |
| Piramal Pharma Limited(this company) | ₹28,246 Cr | — | 3.46 | -3.58% | -3.41% |
AI analysis
AI-generated · google/gemini-2.5-flashPiramal Pharma Limited is listed with a market capitalization of Rs 23814 Cr. The company reported revenue of Rs 9082.38 Cr and a negative profit margin of -367.5%. Its return on equity (ROE) was -357.6%, and return on capital employed (ROCE) was 2.5789%.
Positives
- +Revenue grew by 12% to Rs 9082.38 Cr.
- +Debt-to-equity ratio is 0.65.
- +Promoter pledge is 0% of their holding.
- +Institutions held 27.0905% of shares as of June 2026.
Negatives
- −The company reported a negative profit margin of -367.5%.
- −Return on equity (ROE) is significantly negative at -357.6%.
- −The latest annual net profit for March 2026 was -325.94 Cr, with EPS at -2.46.
- −FII shareholding decreased from 32.226% in August 2023 to 12.5162% in June 2026.
- −Quarterly net profit was -8.83 Cr for March 2026.
Financial Performance
Piramal Pharma Limited generated revenue of Rs 9082.38 Cr, marking a 12% revenue growth. However, the company recorded a negative profit margin of -367.5%. The annual net profit for March 2026 was -325.94, with basic EPS at -2.46 for the same period. More recently, for the quarter ending March 2026, the company reported revenue of Rs 2751.77 Cr and a net profit of -8.83.
Profitability & Returns
The company's profitability metrics show a Negative return on equity (ROE) of -357.6%. The return on capital employed (ROCE) stands at 2.5789%. The profit margin was significantly negative at -367.5%, indicating that the company is incurring substantial losses relative to its revenue.
Balance Sheet
Piramal Pharma Limited has a debt-to-equity ratio of 0.65. The book value per share is Rs 61.34. Further details regarding other balance sheet components are not provided.
Ownership & Pledges
As of June 30, 2026, promoter shareholding was 34.8012%, with DII holding 14.5743% and FII holding 12.5162%. Public shareholding was 38.1083%. There are no promoter shares pledged. The total number of shareholders stood at 461096.
Shareholding Changes
Promoter shareholding in Piramal Pharma Limited has shown minor fluctuations, from 35.0233% in August 2023 to 34.8012% by June 2026. FII holding has decreased from 32.226% in August 2023 to 12.5162% in June 2026. DII holding increased from 7.8257% to 14.5743% over the same period. Public shareholding has increased from 24.925% to 38.1083%.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.